Midwives may independently prescribe, order and administer this drug.
If rubella-susceptible during the antenatal period MMR vaccine should be offered in the immediate postpartum period. Those susceptible should be immunized only if they are not pregnant at vaccination time and if pregnancy is avoided for 3 months following vaccination. MMR Vaccine should not be administered to: (a) during pregnancy, since the possible effect on the fetus is not known; (b) individuals with acute febrile respiratory or other infections, or any acute illness; (c) individuals with a history of sensitivity to neomycin or polymixin; (d) individuals with blood dyscrasias, Iymphomas or other generalized malignancies; (e) individuals with untreated active tuberculosis; (f) individuals undergoing treatment with immunosuppressive agents of any kind.
If rubella-susceptible and exposed to rubella during pregnancy, one should consider the possibility of providing temporary passive immunity through the administration of immune serum globulin (human). Do not give immune globulin concurrently with MMR.
Previous administration of Rho(D) immune globulin or blood products is not a contraindication to postpartum vaccination. Serologic testing 6 to 8 weeks post-vaccination should be carried out to ascertain that seroconversion has occurred.
Store MMR vaccine at 2 to 8 degrees C and protect vaccine from light at all times. Discard reconstituted vaccine if not used within 8 hours. Additional handling and storage requirements for the vaccine, as outlined by the supplier, must be followed.
Whenever vaccines are administered the midwife must send a record of immunization to the physician to whom care is transferred at 6 weeks postpartum. A record of immunization should also be sent to the local public health unit in communities where this is required.
Prior to administration, information must be provided on possible vaccine reactions. Epinephrine (1:1,000) should be available for immediate use in the event of an anaphylactic reaction.
Category L3 – No Data – Probably Compatible
Dosage and Administration:
0.5 mL SC (Do not give IV)